Browse News
Filter News
Found 1,960 articles
-
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
9/27/2023
Arcutis Biotherapeutics, Inc. today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately.
-
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
9/13/2023
AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology.
-
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
9/12/2023
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer harboring AT-rich interacting domain containing protein 1A (ARID1A) mutations and who have progressed on at least one prior line of treatment.
-
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
9/8/2023
BriaCell Therapeutics Corp. today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.
-
Alpenglow Biosciences presents the 3D Spatial Summit, an inaugural event for the field of 3D Spatial Biology to take place on September 21, 2023 in Cambridge, Massachusetts
8/29/2023
Alpenglow Biosciences (Alpenglow), creators of an innovative end-to-end 3D spatial biology platform and suite of quantitative spatial statistical analysis tools, revealed their first annual 3D Spatial Summit scheduled for September 21, 2023 in Cambridge, Massachusetts.
-
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
8/28/2023
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, announced the appointment of Jeff Caravella as Chief Financial Officer.
-
Innovent Announces 2023 Interim Results and Business Updates
8/23/2023
Innovent Biologics, Inc. announces its 2023 interim results and major company business updates.
-
Incyte to Present at Upcoming Investor Conferences - August 22, 2023
8/22/2023
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September.
-
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
8/16/2023
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SINTBILO®.
-
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
8/9/2023
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
-
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
8/9/2023
MorphoSys AG reports results for the second quarter and first half year of 2023.
-
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
8/8/2023
Syros Pharmaceuticals today reported financial results for the quarter ended June 30, 2023 and provided a corporate update.
-
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
8/7/2023
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter and provided a business update.
-
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
8/3/2023
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2023 and provided a business update.
-
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
8/3/2023
Deciphera Pharmaceuticals, Inc. announced that the Company’s Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company.
-
Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
8/3/2023
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended June 30, 2023, and provided a business update.
-
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
8/1/2023
Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.
-
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
7/31/2023
Replimune Group, Inc. (NASDAQ:REPL) and Incyte today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.
-
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
7/24/2023
Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy.
-
The company’s ruxolitinib cream Opzelura led to higher rates of treatment success in children with atopic dermatitis than with a control cream.